Who Owns Organigram Holdings Company?

Organigram Holdings Bundle

Get Full Bundle:

	PESTLE	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Organigram Global Inc.?

Understanding a company's ownership is key to its strategy and market influence. A major shift for Organigram Global Inc. was the significant investment from British American Tobacco (BAT), deepening their partnership and reshaping its capital structure.

Organigram Global Inc., formerly Organigram Holdings Inc., was founded in 2013. It's a licensed producer of cannabis products, offering a wide range including dried flower, edibles, and vapes. As of December 2024, it became Canada's largest cannabis company by market share after acquiring Motif Labs Ltd.

The ownership of Organigram Global Inc. is a mix of institutional investors, public shareholders, and a significant strategic stake held by British American Tobacco (BAT). This partnership, which began with a substantial investment, has evolved, giving BAT a notable influence on the company's direction. The remaining shares are widely held by the public, traded on both the NASDAQ and TSX under the ticker OGI. This dispersed ownership structure, combined with BAT's strategic interest, shapes the company's governance and its approach to market opportunities, including its diverse product lines like those detailed in the Organigram Holdings PESTEL Analysis.

Organigram Holdings Inc. was established in 2013 in Moncton, New Brunswick, Canada, with a foundational goal to become a significant player in the emerging Canadian cannabis market. The company's initial strategy centered on the production of organic and sustainably grown medical cannabis, which helped it carve out an early niche and gain recognition within the industry.

Founding Vision

Organigram's inception was driven by a strong passion for cannabis and an unwavering commitment to product quality.

Early Market Positioning

The company differentiated itself by focusing on organic and sustainable cultivation practices from its early days.

Founders' Identity

While the company's vision is clear, comprehensive public details on all original founders' full names and backgrounds are not extensively documented.

Initial Equity Structure

Precise equity distribution among the founders at the company's inception is not readily available in public records.

Early Investment Landscape

Information regarding early backers, angel investors, or friends and family who invested during the private phase is not widely disclosed.

Founder Agreements

Details on early agreements such as vesting schedules, buy-sell clauses, or founder exits are not typically found in current public filings.

The core principle of producing high-quality cannabis has remained a central element of Organigram's operational philosophy throughout its growth and evolution. Understanding the competitive landscape is crucial for assessing the company's trajectory; one can explore the Competitors Landscape of Organigram Holdings for further context.

Key Tenets of Organigram's Founding

Organigram Holdings Inc. was founded with a clear mission to excel in the Canadian cannabis sector, emphasizing quality and sustainability.

• Establishment in 2013 in Moncton, New Brunswick.
• Initial focus on organic and sustainable medical cannabis.
• Commitment to high-quality product development.
• Vision to become a prominent producer and distributor.

Organigram Holdings SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Organigram's journey from its inception to its current standing has been shaped by significant ownership shifts, notably its transition to the Toronto Stock Exchange in August 2019 and a pivotal strategic investment from a major international player.

The ownership landscape of Organigram Holdings Inc. is dynamic, with a substantial strategic investment from British American Tobacco (BAT) significantly altering its shareholder base. As of June 17, 2025, BAT, through its subsidiary BT DE Investments Inc., holds 13,794,163 shares, representing 10.30% of the company's holdings and is classified as an insider. This stake positions BAT to influence key corporate decisions, including director elections.

Organigram Holdings Inc. Shareholder Breakdown

Organigram's ownership is a mix of strategic investors, institutional funds, insiders, and the general public. Understanding these key stakeholders is crucial for assessing the company's direction.

• British American Tobacco (BAT): Holds 10.30% as of June 17, 2025, with strategic aims for up to 45% equity.
• Institutional Investors: As of March 31, 2025, entities like Tidal Investments LLC (1.88%) and Renaissance Technologies, LLC (0.75%) are notable holders.
• Individual Insiders: Collectively own approximately 0.175% to 0.212% of shares.
• General Public and Other Individual Investors: Constitute the largest segment, holding between 66.5% and 85.96% of the company's stock.
• The company's Mission, Vision & Core Values of Organigram Holdings are supported by its diverse shareholder base.

Organigram Holdings PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors for Organigram Global Inc. was established at the Annual General and Special Meeting of Shareholders on March 24, 2025. This board is responsible for overseeing the company's strategic direction and governance. The members include Chairman Peter Amirault, Dexter John, Stephen Smith, Geoffrey Machum, Sherry Porter, Marni Wieshofer, Simon Ashton, Karina Gehring, Craig Harris, and CEO Beena Goldenberg.

The voting power within Organigram is structured to reflect significant shareholder influence. While common shares typically operate on a one-share-one-vote basis, the investment by British American Tobacco introduced non-voting Class A convertible preferred shares. These preferred shares can be converted into voting common shares, but only if the conversion does not push British American Tobacco's voting interest above 30%. This arrangement allows British American Tobacco considerable sway in shareholder decisions, including director elections and major corporate actions, without necessarily holding a majority of the common voting stock. There have been no reported proxy battles or activist investor campaigns that have significantly altered this established decision-making framework, highlighting the structured influence of British American Tobacco as a key aspect of Organigram Holdings Inc. corporate governance.

Understanding Shareholder Influence

The composition of the board and voting rights are critical for understanding Organigram Holdings ownership. British American Tobacco's nominees on the board and their convertible share structure significantly impact voting outcomes.

• British American Tobacco has three nominees on the board.
• Voting is generally one-share-one-vote for common shares.
• Convertible preferred shares limit voting interest to 30%.
• This structure grants significant influence to British American Tobacco.
• Understanding these dynamics is key to grasping Organigram Holdings Inc. shareholders.

Organigram Holdings Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Organigram's ownership landscape has been significantly reshaped over the past few years, marked by substantial strategic investments and key acquisitions. These shifts reflect a dynamic approach to growth and market positioning within the evolving cannabis industry.

The company's strategic maneuvers, including the significant investment from British American Tobacco and the acquisition of Motif Labs Ltd., underscore a commitment to expanding its market presence and operational capabilities. These actions are indicative of broader consolidation trends observed within the cannabis sector, where companies are actively seeking to strengthen their competitive positions through mergers and strategic alliances.

Strategic Investment and Expansion

British American Tobacco's continued investment, totaling C$124.6 million by February 2025, highlights a strong partnership. The 'Jupiter' fund, with approximately C$59 million available as of May 2025, is earmarked for international expansion and new growth opportunities.

Market Consolidation and Growth

The acquisition of Motif Labs Ltd. for C$91.3 million in December 2024 solidified Organigram's position as a market leader. This move aligns with industry-wide consolidation, aiming to achieve greater economies of scale and market share.

Capital Raising and Leadership Evolution

Organigram successfully raised C$28.8 million in April 2024 through a public offering. The company also saw leadership changes, with Greg Guyatt appointed CFO in January 2024 and CEO Beena Goldenberg set to retire at the end of the fiscal year ending September 30, 2025.

Ownership Trends and Future Outlook

Increased institutional ownership is a notable trend, with major investors holding significant stakes. While founder dilution is a natural consequence of public offerings and strategic investments, Organigram's focus on international expansion, supported by the Jupiter fund, suggests potential for further ownership shifts and strategic partnerships.

Organigram Holdings Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔